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Untreated maple syrup urine disease (MSUD) results in mental and physical disabilities and often leads to neonatal
death. Newborn-screening programs, coupled with the use of protein-modified diets, have minimized the severity
of this phenotype and allowed affected individuals to develop into productive adults. Although inheritance of
MSUD adheres to rules for single-gene traits, mutations in the genes for E1a, E1b, or E2 of the mitochondrial
branched-chain a-ketoacid dehydrogenase complex can cause the disease. Randomly selected cell lines from 63
individuals with clinically diagnosedMSUDwere tested by retroviral complementation of branched-chaina-ketoacid
dehydrogenase activity to identify the gene locus for mutant alleles. The frequencies of the mutations were 33%
for the E1a gene, 38% for the E1b gene, and 19% for the E2 gene. Ten percent of the tested cell lines gave
ambiguous results by showing no complementation or restoration of activity with two gene products. These results
provide a means to establish a genotype/phenotype relationship in MSUD, with the ultimate goal of unraveling
the complexity of this single-gene trait. This represents the largest study to date providing information on the
genotype for MSUD.
Maple syrup urine disease (MSUD;MSUD type Ia [MIM
248600], MSUD type II [MIM 248610], MSUD type Ib
[MIM 248611]) is a rare inborn error of metabolism
affecting !1 in 180,000 newborn infants in the general
population (Peinemann and Danner 1994; Chuang and
Shih 1995; Danner and Doering 1998). Despite its rare
occurrence, MSUD is found in all racial and ethnic
groups throughout the world (Danner and Elsas 1989).
Neurological complications and death in the neonatal
period can result from this inability to catabolize the
branched-chain amino acids (BCAA) leucine, isoleucine,
and valine. The pathophysiology of untreated MSUD is
not well understood. Newborn-screening programs in
most states and in several foreign countries detect those
individuals at risk for expressing the disease. Affected
individuals are protein intolerant and must be nurtured
with synthetic diets that limit the intake of these essential
BCAA (Elsas and Acosta 1988). These protein-modified
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diets enable near-normal growth and development for
affected individuals but must be tailored to the individ-
ual, demonstrating one aspect of the complexity of this
single-gene trait (Scriver and Waters 1999; Dipple and
McCabe 2000).
The inability to catabolize the BCAA results from de-
fective function of the branched chain a-ketoacid de-
hydrogenase (BCKD) complex. BCKD oxidatively de-
carboxylates the branched-chain a-ketoacids (BCKA)
formed by the transamination of the BCAA. This mi-
tochondrial multienzyme complex is encoded entirely by
nuclear genes. Four protein products impart catalytic
function, and two other protein products are used to
regulate BCKD activity-state in the different tissues (Gil-
lim et al. 1983; Wagenmakers et al. 1984). This regu-
lation is necessary to prevent the depletion of BCAA,
since BCKD is present in all cells. The need for this wide
tissue distribution of BCKD is not understood.
Of the four genes that impart catalytic function, three
encode proteins with specificity for the BCKA substrates.
The fourth catalytic gene product also functions with
othermitochondrial complexes (Yeaman1989).Although
inheritance of MSUD adheres to a simple autosomal re-
cessive pattern, mutations in each of these three BCKD-
specific genes have been shown to cause MSUD. Two of
these genes encode subunits (E1a [Z14093] and E1b
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Table 1
BCKD Activity in Lymphoblast Lines with Defined Genotypes, from Patients with MSUD
CELL LINE
MUTANT
GENE MUTATION
MEAN  SD TOTAL BCKD ACTIVITYa
(pmol 14CO2/mg protein/3 h)
Not
Transduced E1a E1b E2
EM408 E1a Y438Nb 0  0 166  51 0  0 0  0
EM1952c E1b N176Y/R324X 24  2 10  1 364  89 19  6
EM3069d E2 1031GrA/ (20-kb del) 71  3 71  14 82  21 149  43
DG75 None 6,158  626 ND ND ND
a All cells were treated with 1mM a-chloroisocaproate for 10 min prior to addition of substrate to induce
ability to measure full activity of the BCKD complex. ND p not done.
b Known Mennonite cell line.
c From McConnell et al. (1997).
d From Herring et al. (1992).
Figure 1 Western blot of BCKD proteins in mitochondria. Mi-
tochondria were prepared from EM6229 cells without viral transduc-
tion or after transduction with either the E2 or E1b vector, and 20 mg
were resolved for immunoblots. Mitochondria from DG75 cells serve
as a wild-type control line.
[M55575]) that form a heterotetramer that uses thiamin
pyrophosphate as a cofactor to decarboxylate the BCKA
(Ævarsson et al. 2000). The third gene product, the acyl-
transferase (E2 [X66785]) core protein, transfers the
branched-chain acyl moiety to coenzyme A (Yeaman
1989; Reed and Hackert 1990).
The majority of mutations described to date have been
in the gene that encodes the E1a subunit (Danner and
Doering 1998). It remains to be shown whether any one
of these three genes has an increased tendency toward
mutation. Although all the genes have been character-
ized and their chromosomal location identified, no easy
method is available to determine whether the E1a, E1b,
or E2 gene harbors the mutant alleles. The only mutant
allele found with any frequency exists in the Mennonite
community and is associated with a founder effect (Dan-
ner and Doering 1998).
Finding a simple, reliable method to identify the spe-
cific mutant gene that causes MSUD from the three pos-
sible choices has presented a challenge. Western blots
can be used to define individuals with MSUD who lack
the E2 protein (Danner et al. 1985). However, reduction
in the antigenic presence of E1a, E1b, or both can result
from mutations in either gene, because the ability to
form the a2b2 tetramer is affected. In some MSUD cell
lines, the proteins of the complex are antigenically in-
distinguishable from those seen in cells with normal ac-
tivity. Thus, immunoblots have limited value in helping
to identify the gene harboring the mutant alleles.
Enzyme-activity measurements in cultured cells de-
rived from patients are used to confirm the clinical di-
agnosis of MSUD made by quantification of plasma
BCAA concentration. We and others have shown that
impaired BCKD activity is functionally restored to cul-
tured cells by episomal addition of a wild-type cDNA
for the defective gene (Litwer et al. 1989; Koyata et al.
1993; Mueller et al. 1995). Here we use this BCKD-
activity-complementation approach to identify the gene
harboring the mutant alleles. Retroviral plasmids hold-
ing the wild-type cDNA sequence were constructed for
each of the three MSUD-specific genes in order to ef-
fectively and efficiently transduce both fibroblasts and
lymphoblasts. Cell lines with defined mutations from
individuals with MSUD were used to establish condi-
tions for BCKD assay after transduction. As shown in
table 1, the return of function to BCKD is clearly evident
by 72 h after transduction of lymphoblasts and can spe-
cifically distinguish the defective gene despite an esti-
mated transduction efficiency of only 30%. Production
of the subunit encoded by the viral vector was dem-
onstrated by western blot of mitochondrial protein from
an E2-negative cell line transduced with the E2 and E1b
vectors (fig. 1). Efficiency of transduction in fibroblast
cultures is 170% by 48 h; thus, assays of BCKD activity
can be performed at this time (table 2).
This enzyme-complementation analysis was applied to
63 cell lines from individuals with MSUD and without
a known Mennonite ancestor. This represents the largest
single study sample used for analysis of the MSUD ge-
notype. No other qualification was placed on sample
selection. The cell lines were obtained from physicians
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Table 2
BCKD Activity in Fibroblast Lines with Unknown Genetic
Mutations, from Patients with MSUD
CELL
LINE
MEAN  SD TOTAL BCKD ACTIVITYa
(pmol 14CO2/mg protein/3 h)
Not
Transduced E1a E1b E2
EM15496 11  4 2,437  13 8  0 10  2
EM5621 1  9 5  0 2,128  58 17  1
EM4566 22  3 29  12 26  4 2,112  453
EM1118b 3,281  113 ND ND ND
a Conditions for the assay are described in the text and in table 2.
ND p not done.
b Control cell line.
Figure 2 Percentage of cell lines with mutations in each of three
genes that cause MSUD. A, Results of 63 cell lines using restoration
of BCKD activity assay. Twenty-nine females and 34 males, excluding
those with known Mennonite heritage, were tested. B, Summary of
percentages based on mutations described elsewhere.
throughout the world and included individuals from
North, Central, and South America; Europe; and Asia.
This sample includes 34 males and 29 females, in ac-
cordance with the autosomal recessive nature of MSUD.
As depicted in figure 2A, mutations in the gene for E1b
on chromosome 6 are approximately equal to the fre-
quency of E1a mutations, whereas those of E2 are some-
what less common. In contrast, 52% of the previously
characterized mutant alleles were the result of defects in
the gene for the E1a subunit on chromosome 19, and
36% were defects in E2, as summarized in figure 2B
(Chuang and Shih 1995; Danner and Doering 1998).
Results from five lymphoblastoid lines and one fibro-
blast line were ambiguous when this BCKD comple-
mentation analysis was used. For four cell lines, no stim-
ulation of residual activity was observed with any
subunit in three separate transductions for each cell line.
The other two cell lines exhibited !10% increases in
residual activity with two different subunits. Five of the
six cell lines have residual activity 12% of wild-type
BCKD activity, a condition that has been used to define
an “intermittent” or “intermediate” form ofMSUD (Pei-
nemann and Danner 1994). In contrast, the majority of
the other 57 cell lines have residual activity that is !2%
of wild-type BCKD activity (table 3). Western blots of
mitochondrial proteins from five of the six cell lines that
gave ambiguous results show the antigenic presence in
all subunits. One lacked the antigenic presence of both
E1a and E1b. Another cell line that was found to be
ambiguous in the lymphoblast assay was resolved when
fibroblasts from the patient were analyzed; this was
likely a result of the higher transduction efficiency for
fibroblasts. Unfortunately, fibroblasts are not available
for all patients studied. Definition of the specific mu-
tations in the cells with ambiguous complementation
data will resolve these questions and offer a clearer un-
derstanding of MSUD variability, especially regarding
the “intermediate” phenotype (Peinemann and Danner
1994).
The somewhat lower frequency of mutations associ-
ated with the E2 gene on chromosome 1 may be real,
but other explanations are possible. First, if the cell lines
that give ambiguous results have mutations in the E2
gene, then an equal distribution of mutations among the
three genes would result. A second explanation may be
that the E2 mutations are being missed at the clinical
level. As seen in table 3, individuals with E2 mutations
can have higher residual activity than that found in cell
lines with mutations in the other two genes. In some
individuals there is no antigenic protein being produced
(fig. 1) and yet some decarboxylation of the ketoacid
substrate occurs (Danner et al. 1985; Ellerine et al.
1993). Mutations in E2 have also been associated with
the “thiamin-responsive” form of MSUD (Danner et al.
1975; Fernhoff et al. 1985; Ellerine et al. 1993). One
possible explanation for the thiamin response is that the
E1 decarboxylase, which uses thiamin pyrophosphate as
a cofactor in the reaction mechanism, can function in-
dependently of the E2 protein. The branched-chain acyl-
thiamin pyrophosphate intermediate formed in the de-
carboxylation reaction is displaced by the excess thiamin
pyrophosphate in the cell, thus allowing the enzyme to
catalyze another round of decarboxylation (Herring et
al. 1992; Danner and Doering 1998). The independent
function of E1 could explain the higher residual activity
observed for the E2 mutant cell lines. In some cases this
activity could be high enough to prevent the full clinical
phenotype, and therefore these individuals are never
classified as having MSUD.
The ability of the enzyme complementation analysis
to identify the mutant genes was confirmed by nucleotide
sequence analysis of the indicated mutant gene with the
primers listed in table 4. Results for one patient from
each complementing group are reported in table 5. Pa-
rental cell lines for each proband were used to confirm
the transmission of the mutant allele. The three examples
all happened to be homozygous for the mutant allele,
which is unusual for MSUD, since most probands thus
far characterized are compound heterozygotes. Another
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Table 3
Distribution of MSUD Cell Lines, Based on Mutant Gene and
Percent Residual Activity of BCKD Above That in the Control Lines
MUTANT GENE
NO. OF MSUD CELL LINES IN WHICH
RESIDUAL ACTIVITY COMPARED WITH
THAT IN WILD-TYPE BCKD IS
!2% 2%–10% 110%
E1a 19 1 1
E1b 23 0 1
E2 9 3 0
Ambiguousa 1 3 2
a BCKD activity was complemented with more than one subunit,
or there was no complementation.
Table 4
Primers Used to Prepare DNA for Nucleic Acid Sequence Analysis
Gene and Primer
Sequence
(5′r3′)
Position in
Coding Sequence
Annealing
Temperature
(C)
E1a:
Forward CTAAACCGTGGTTTGAGCCA 32–52 54
Reverse GCGTACGCCGCCCCCACCGCC 679–658
Forward GGCGGTGGGGGCGGCGTACGC 685–679 54
Reverse GGTGGGGGTGGGCTGAGCAGG 1374–1353
E1b:
Forward CGGGACTACGGGCAAACTCA 191–210 58
Reverse AGAGCCCCATGACCAACACAGCCCC 628–604
Forward TGGCTACTCAGGCTCAGG 75–92 50
Reverse TCCCCAGAGCGATAGCGATACTTG 565–542
Forward GGAATCGGAATTGCGGTCACTGGAG 444–468 58
Reverse tcgcgaattcCAGTTACGTTAATGTCAGGGG 1286–1267
E2:
Forward GCTGCAGTCCGTATGCTGA 18–36 54
Reverse CTAGTAGCATAAAAGCTGGG 1456–1434
unexpected result was that the mutant allele defined for
the E1a gene in proband EM5579 was the allele that
accounts for 199% of MSUD in the Mennonite popu-
lation. It was previously thought that this allele was not
found with greater frequency than other mutations in
this gene in the general population. This proband’s fam-
ily has no known Mennonite heritage and the mating is
not consanguineous. As more of the cell lines with mu-
tations in this gene are defined, it will become possible
to ascertain the true frequency of this mutant allele in
the general population.
Mutations described in the E1b gene are for a pro-
band who is the product of a consanguineous mating,
of Turkish origin. The mutant allele results in a V251A
substitution in the protein. According to the crystal
structure coordinates (Ævarsson et al. 2000), the valine
residues are on the surface of the a2b2 tetramer, pos-
tulated to be in a region of interaction with the E2 core
protein. It is not yet known how this alanine substi-
tution in this position disrupts the function of BCKD
(Ævarsson et al. 2000). A second Turkish proband
(also the product of a consanguineous mating) who
complemented with the E1b subunit was homozygous
for the nucleotide change 1149TrA, introducing a stop
codon at Y383. These results argue against the presence
of a common allele within families of Turkish decent.
The homozygous mutation in the E2 gene in proband
EM5591 produces an R462P amino acid substitution.
At present it is not known whether this is a consan-
guineous mating. The R462 residue is just C-terminal
to the putative coenzyme A binding site of the protein
(Danner et al. 1989). The crystal structure for the E2
protein has not been solved, so it would be highly spec-
ulative to predict the way in which this amino acid sub-
stitution might change the ability to form the CoA ester.
The complex nature of single-gene traits has been at-
tributed to variation in specific mutation sites, amino
acid substitutions in the protein product, and the ge-
nomic background of affected individuals (Scriver and
Waters 1999; Dipple and McCabe 2000). Variation in
MSUD can also result from the fact that mutations in
three different genes can produce a similar phenotype.
The products of these genes must interact in a multien-
zyme complex to achieve their cellular function. To be-
gin to unravel the complexity of MSUD we must first
ask whether there is a variation in the occurrence of
mutations in the three genes. Here we used this rescue
technique to identify the defective subunit, and therefore
the gene, with the mutant alleles. The method was ef-
fective in 90% of cell lines tested. Previously, it was
necessary to sequence all three genes and to exclude
polymorphic changes. Now only one gene needs to be
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Table 5
Nucleic Acid Changes in Mutant Genes Identified by BCKD Complementation Analysis
CELL LINE
MUTANT
GENE
MEAN  SD TOTAL BCKD ACTIVITYa
(pmol 14CO2/mg protein/3 h)
NUCLEOTIDE CHANGEb
AMINO ACID
CHANGEBaseline Rescued
EM5579 E1a 0  1 136  6 1312TrA Y438N
EM608 E1b 37  11 123  18 752TrC V251A
EM5591 E2 318  54 569  29 1385GrC R462P
a BCKD activity is defined in table 2.
b All three probands were homozygous for the indicated change, and both parental lines in each family were heterozygous for
the mutant allele.
scrutinized for nucleic acid changes. It appears that mu-
tations occur in each of the three genes, and analysis of
additional cell lines will allow a better estimation of the
exact frequency. When amino acid substitutions result
from these nucleic acid changes, it may be possible, in
the future, to design specific reagents that will interact
with the mutant protein in a way that alters the structure
into a functional form. These reagents would offer a new
and improved therapy for individuals with MSUD.
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